Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.

Exclusion Criteria

• •1. Discontinued prematurely from the preceding study ((MS-F202EXT, MS-F203EXT, or MS-F204EXT).
• •2. Any prior history of seizure, epilepsy, or other convulsive disorder.
• •3. Any clinically significant abnormal laboratory values.
• •4. New history of moderate or severe renal impairment.
• •5. New history of angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator.
• •6. Any significant change in overall health that would preclude subject's participation in the study, in the opinion of the Investigator.
• •7. Known allergy to pyridine-containing substances or any of the inactive ingredients of the fampridine-SR tablet
• •8. Received an investigational drug, except fampridine-SR under the preceding study (MS-F202EXT, MS-F203EXT, or MS-F204EXT), within the last 30 days, or the subject is scheduled to enroll in an investigational drug at any time during the study.
• •9. A history of drug or alcohol abuse within the past year.
• •10. Treatment with other forms of fampridine or 4-AP (e.g., compounded formulation of 4-AP) or 3,4-diaminopyridine (3,4-DAP).